BioMimics 3D Vascular Stent System
Veryan Medical, Ltd. · Decision date Feb 19, 2026
What did the FDA decide?
FDA records P180003/S014 as a supplement to PMA P180003, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 19, 2026.
FDA approval order statement
changes to the stent surface finish inspection criteria on stents lengths from 60mm to 125 mm
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Feb 19, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P180003/S014
- Regulatory pathway
- PMA supplement
- Applicant
- Veryan Medical, Ltd.
- Product code
- NIP
- Decision code
- OK30
- Decision date
- Feb 19, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.
- Applicant
- Veryan Medical, Ltd.
- Product code
- NIP
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P180003/S013 · Related supplement
BioMimics 3D Vascular Stent System
P180003/S014 received
Application receipt date recorded by FDA.
P180003/S014 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P180003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
BioMimics 3D Vascular Stent SystemP180003/S013 | Veryan Medical, Ltd. | PMA supplement | Jan 7, 2026 | FDA |
Explore the linked device profile
Other records with product code NIP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Supera Peripheral Stent SystemP120020/S037 | Abbott Vascular (Idef Technologies Inc) | PMA supplement | Nov 6, 2026 | FDA |
| Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Cordis US Corporation | PMA supplement | Oct 15, 2026 | FDA | |
| Biotronik AG | PMA supplement | Sep 11, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Veryan Medical, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Unit 15, City Business Centre, Brighton Rd., Horsham, RH13 5BB
Sources and methodology
- Original FDA record: P180003/S014
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


